Page last updated: 2024-08-21

pyrazines and Bone Marrow Failure Syndromes, Congenital

pyrazines has been researched along with Bone Marrow Failure Syndromes, Congenital in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gupta, K; Klimenkova, O; Klimiankou, M; Kuznetsova, I; Meyer, J; Moore, MA; Skokowa, J; Welte, K; Zeidler, C	1

Other Studies

1 other study(ies) available for pyrazines and Bone Marrow Failure Syndromes, Congenital

Article	Year
Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells. Blood, 2014, Apr-17, Volume: 123, Issue:16 Topics: Antigens, CD34; Boronic Acids; Bortezomib; Cell Differentiation; Cells, Cultured; Congenital Bone Marrow Failure Syndromes; Granulocytes; HEK293 Cells; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lymphoid Enhancer-Binding Factor 1; Neutropenia; Proteolysis; Pyrazines; STAT5 Transcription Factor	2014

Article

Year

Bortezomib inhibits STAT5-dependent degradation of LEF-1, inducing granulocytic differentiation in congenital neutropenia CD34(+) cells.

Blood, 2014, Apr-17, Volume: 123, Issue:16

Topics: Antigens, CD34; Boronic Acids; Bortezomib; Cell Differentiation; Cells, Cultured; Congenital Bone Marrow Failure Syndromes; Granulocytes; HEK293 Cells; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lymphoid Enhancer-Binding Factor 1; Neutropenia; Proteolysis; Pyrazines; STAT5 Transcription Factor

2014